Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

A "Light Bulb" Moment For People With Dementia
Change the lighting; improve your health. It"s a strategy researchers from Case Western Reserve University"s Frances Payne Bolton School of Nursing and the School of Medicine, the Geriatric Research Education and Clinical Center at the Louis Stokes Cleveland Veterans Affairs Medical Center (GRECC), Rensselaer Polytechnic Institute"s Lighting Research Center and GE Consumer & Industrial have begun to test in a long-term care facility where daylight, which has proven health benefits, is not readily available.

Obama Adviser Jarrett Praises Supreme Court Nominee Sotomayor, Responds To Critics
White House senior adviser Valerie Jarrett in a speech on Monday at the National Partnership for Women & Families" annual luncheon touted Supreme Court nominee Sonia Sotomayor"s credentials and responded to critics who have attacked the judge"s qualifications and past statements, the Washington Post"s "44" reports. Jarrett noted that Sotomayor has more federal experience than any other Supreme Court justice in 100 years. "You can imagine our surprise when people started saying maybe she wasn"t qualified," Jarrett said. She continued that Sotomayor also has an "incredible, rich personal story" that represents the "American Dream." When Sotomayor "talk[ed] about how important that upbringing was, what that will help her bring to the bench -- just as I might add Justice Alito did during his confirmation -- suddenly her background comes into question," Jarrett said, adding that this is a "double standard." Critics have attacked Sotomayor"s comment during a speech at the University of California-Berkeley that she would "hope that a wise Latina woman with the richness of her experiences would more often than not reach a better conclusion than a white male who hasn"t lived that life." Alito during his confirmation hearing said, "When I get a case about discrimination, I have to think about people in my own family who suffered discrimination because of their ethnic background or because of religion or because of gender. And I do take that into account."Jarrett said of Sotomayor, "I can tell you we really don"t have anything to worry about." She added that Sotomayor "will be far more prepared than anybody else, which is often the case with women. She will make us all proud" (Brown/Leiby, "44," Washington Post, 6/15).
News of the day
Journal For The Sociçİtçİ De Pathologie Exotique To Be Published And Distributed By Springer
As of January 2010, the Bulletin de la Sociçİtçİ de Pathologie Exotique will join Springer"s publishing program. Founded in 1908 by Nobel Laureate Louis-Alphonse Laveran, the society celebrated its centenary last year. It plays a major role in the promotion of health issues and information on tropical pathology.
Nutrition

Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo(R)

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) announced that the U.S. Food and Drug Administration (FDA) has informed the company that it should expect to receive formal notice of a three month extension of the review period for the new drug application (NDA) for Intermezzo(R) (zolpidem tartrate sublingual tablet). The Intermezzo(R) NDA had been assigned a Prescription Drug User Fee Act (PDUFA) date of July 30, 2009. Under this revised timeline, Transcept now anticipates action from the FDA on the NDA on or before October 31, 2009. In the normal course of the Intermezzo(R) NDA review, the FDA previously requested additional information regarding middle of the night dosing instructions. As both the request and the Transcept response occurred late in the review cycle, the FDA has informed the company that it will extend the NDA review cycle by three months to consider the new information. Glenn A. Oclassen, President and Chief Executive Officer, commented, "Although we have not yet received a formal written notification from the FDA, our conversations with them indicate that additional review time for the Intermezzo(R) NDA will be necessary. We felt it our responsibility to inform shareholders in advance of a formal FDA notification and will update our shareholders as appropriate after such notice is received." Mr. Oclassen added, "We appreciate the willingness of the FDA to take the time necessary to fully consider our recent amendment to the Intermezzo(R) NDA. We remain confident in the strength of our regulatory submissions and look forward to working with the FDA as it completes its review. Our goal remains to provide a new and important therapeutic for those patients who suffer from middle of the night awakenings with difficulty returning to sleep." About Intermezzo(R) Intermezzo(R) Phase 3 clinical trials have been completed and, on September 30, 2008, Transcept submitted an NDA to the FDA, which was accepted for filing and assigned a PDUFA date of July 30, 2009. On June 10, 2009 Transcept received notice that the FDA would require up to an additional three months to complete its review of the Intermezzo(R) NDA. Under the revised timeline, Transcept now anticipates action from the FDA on the NDA on or before October 31, 2009. If approved within the anticipated time frame, Intermezzo(R) will be the first commercially available sleep aid designed specifically for use in the middle of the night when patients awaken and have difficulty returning to sleep. As part of the NDA submission, Transcept requested that the FDA grant three years of Hatch-Waxman marketing exclusivity to Intermezzo(R). Transcept is also actively pursuing patents to cover Intermezzo(R) in the United States and key non-U.S. markets. About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to "Transcept Pharmaceuticals, Inc." and its NASDAQ ticker symbol to "TSPT." Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the timing of potential FDA approval of the Intermezzo(R) NDA and Intermezzo(R) being the first commercially available sleep aid in the United States in its target indication. Transcept may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Transcept makes, including risks related to: the opinion of the FDA on the sufficiency of the NDA to support marketing approval of Intermezzo(R); FDA review of the additional information recently provided by Transcept; the grant by the FDA and maintenance of exclusivity to Intermezzo(R) under Hatch-Waxman; commercial acceptance of Intermezzo(R), if approved; unforeseen expenses related to FDA approval, commercialization or the business of Transcept generally; Transcept dependence on third parties to manufacture Intermezzo(R); obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo(R); and, if sought, the ability of Transcept to obtain additional funding to support its business activities. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law. Transcept Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009